Screener
Jazz Pharmaceuticals JAZZ Gross Carrying Amount
Gross Carrying Amount at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsGross.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | March 31, 2026 / Remaining Weighted-Average Useful Life(In years) | March 31, 2026 / Gross Carrying Amount | March 31, 2026 / Accumulated Amortization | March 31, 2026 / Net Book Value | December 31, 2025 / Gross Carrying Amount | December 31, 2025 / Accumulated Amortization | December 31, 2025 / Net Book Value |
|---|---|---|---|---|---|---|---|
| Acquired developed technologies | 6.6 | $8,092.6 | $(3,888.8) | $4,203.8 | $8,194.6 | $(3,765.1) | $4,429.5 |
| Manufacturing contracts | — | 1.3 | (1.3) | — | 12.6 | (12.6) | — |
| Trademarks | — | 2.9 | (2.9) | — | 2.9 | (2.9) | — |
| Total finite-lived intangible assets | $8,096.8 | $(3,893.0) | $4,203.8 | $8,210.1 | $(3,780.6) | $4,429.5 |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's gross carrying amount?
- Jazz Pharmaceuticals (JAZZ) reported gross carrying amount of $8.1B in Q1 2026.
- How has Jazz Pharmaceuticals's gross carrying amount changed year-over-year?
- Jazz Pharmaceuticals's gross carrying amount increased by 2.5% year-over-year, from $7.9B to $8.1B.
- What is the long-term trend for Jazz Pharmaceuticals's gross carrying amount?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's gross carrying amount has grown at a 19.3% compound annual growth rate (CAGR), from $3.4B to $8.21B.
Ask your AI about Jazz Pharmaceuticals's gross carrying amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude